Skip to main content

Table 5 3-Year PFS and OS Rates

From: A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix

  No. of patients The 3-year PFS (%) P-value The 3-year OS (%) P-value
All patients 24 87.5 - 91.5 -
Stage      
  IIa2 3 3/3   3/3  
  IIb 18 88.9   88.9  
  IIIb 3 2/3 0.360 3/3 0.710